

### **CERTIFICATE OF ANALYSIS**

Purified **AAV9-CMV-Luciferase** vectors (19-433)

(for research use only)

**Lot No.** 19-433

# **Storage Conditions**

The AAV9 vectors should be stored at -80°C. (long term)

#### **Shelf Life**

4 years when stored at -80°C.

### **Shipping Conditions**

ICE PACK

## **Description**

- The AAV9-CMV-Luciferase vectors were produced in insect Sf9 cells by dual infection with rBV – inCap9-inRep-kozak-hr2 (V289) and rBV- CMV-Luciferase (AVA13).

The vectors were purified through 2 rounds of CsCl ultracentrifugations. The CsCl was removed through buffer exchange with 2 PD-10 desalting columns. The final AAVs were buffer-exchanged to PBS plus 0.001% pluronic F68.

**AAV9-CMV-Luciferase** vectors are for research use only, not for any human purposes.


### **QPCR Titer**

Lot 19-433: 2E+13 vg/mL (final diluted)



# **Quality Control Data**

The vectors were treated through 0.2um sterilized filters. SDS-PAGE and SimplyBlue Staining (Invitrogen) verified the purity of the vectors. Real-time PCR analysis determines the titers of the AAV samples.



Lane 1: Control AAV9, 1e11vg loaded

Lane 3: 19-433, AAV9-CMV-Luciferase, 1e11vg loaded

Fig. 1: SDS-PAGE and Simply Blue Staining of purified AAV9-CMV-Luciferase (19-433).



# Plasmids map




Fig. 2. Diagram of plasmid used to generate rBV- inCap9-inRepCap-kozak-hr2 (V289).






Fig. 3. Diagram of plasmid used to generate rBV- CMV-Luciferase (AVA13).

Approved by: Monday, September 13, 2021.